ALSPW Spineway SAS

Spineway : Signature of an exclusive agreement with the Japanese distributor MURANAKA Medical Instruments

Spineway : Signature of an exclusive agreement with the Japanese distributor MURANAKA Medical Instruments



Signature of an exclusive agreement with the Japanese distributor MURANAKA Medical Instruments

Spineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, announces the signature of an exclusive agreement for the distribution of its products in Japan with MURANAKA Medical Instruments.

This agreement follows on the heels of the approval last October by the Japanese health authorities of Spineway’s Mont-Blanc MIS minimally invasive surgical line. Thanks to established know-how on the Asian continent, Spineway will be able to rely on the sales network and expertise of one of the biggest importers/distributers of medical equipment in Japan to distribute its products on this territory.

Based in Osaka, MURANAKA boasts annual revenue of over 300 million euros and is established in Japan’s largest cities. It has a neurosurgery division and distributes a wide range of equipment and consumables (implants) to the main Japanese hospitals.

Stéphane Le Roux, Chairman and CEO of Spineway, said: “We are honored by and pleased with this partnership with MURANAKA, which is the best partner possible for the promotion of our Mont-Blanc MIS line in Japan. As soon as is feasible, we will assist MURANAKA’s teams and provide guidance as to the specifics and advantages of the Spineway systems in order to develop sales of our premium implants in Japan.”

Thanks to this agreement, Spineway will be able to distribute its implants on one of the world’s largest spinal-surgery markets and spur its sales with higher added value.

Upcoming: 26 May 2020 – General Meeting

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW

Contacts:

SPINEWAY



Shareholder-services line

Available Tuesday through Thursday

(10 a.m. – 12 p.m.)

+33 (0)811 045 555
Eligible PEA / PME



ALSPW



Euronext Growth
Aelium - Fiannce & communication



Investor relations

Solène Kennis

Attachment

EN
23/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : First-quarter 2025 revenue of €2.8 million

Spineway : First-quarter 2025 revenue of €2.8 million Press release         Ecully, April 16, 2025 – 7.00 p.m. SPINEWAY First-quarter 2025 revenue of €2.8 million In thousands of euros20252024Change as a %Q1 revenue2,8283,070-8% Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base. The development of export sales...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€

SPINEWAY : Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€ Communiqué de presse          Ecully, le 16 avril 2025 – 19h SPINEWAY Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€ En milliers d’euros20252024Variation en %CA 1er trimestre2 8283 070- 8% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a réalisé sur le 1er trimestre 2025 un chiffre d’affaires de 2,8 M€, stable par rapport au 4ème trimestre 2024 et en recul de 8% par rapport au chiffre d’affaires du 1er trimestre...

 PRESS RELEASE

Spineway : Consolidated 2024 annual results - Operating income close t...

Spineway : Consolidated 2024 annual results - Operating income close to breakeven Press release         Ecully, March 24, 2025 – 6 p.m. SPINEWAY Consolidated 2024 annual results Annual revenue of €12 million (+14%)Operating income close to breakevenReduction in net loss In thousands of eurosConsolidated accounts20242023Revenue11,95010,519Cost of sales(3,699)(3,309)Gross margin% of revenue8,25069%7,21069%Net operating expensesOf which running costs(9,131)(3,900)(11,727) (5,424)Of which personnel expenses(4,890)(5,659)Operating income/(loss)(881)(4,517)Financial income/(expense)Includin...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2024 consolidés - Résultat d’exploitation...

SPINEWAY : Résultats annuels 2024 consolidés - Résultat d’exploitation proche de l’équilibre Communiqué de presse          Ecully, le 24 mars 2025 –18h SPINEWAY Résultats annuels 2024 consolidés Chiffre d’affaires annuel de 12 M€ (+ 14%)Résultat d’exploitation proche de l’équilibreRéduction de la perte nette En milliers d'eurosComptes consolidés20242023Chiffre d'affaires11 95010 519Coût des ventes-3 699- 3 309Marge brute% du CA8 25069%7 21069%Coûts nets d’exploitationDont coûts de fonctionnement- 9 131-3 900- 11 727 - 5 424Dont charges de personnel- 4 890- 5 659Résultat d’exploitati...

 PRESS RELEASE

SPINEWAY : Point sur la procédure judiciaire contre Strategos

SPINEWAY : Point sur la procédure judiciaire contre Strategos Communiqué de presse          Ecully, le 21 mars 2025 – 8h45 SPINEWAY Point sur la procédure judiciaire contre Strategos Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que la Cour d’appel du Deleware (United States Court of Appeals for the third circuit) a décidé, dans un jugement rendu le 19 mars 2025, de confirmer la décision rendue en première instance et déboutant le groupe Spineway de sa demande d’exécution de la sentence arbitrale rend...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch